This is an interesting story. As Morgans points out, one peer comparison is ANI Pharmaceuticals INC (see attached link) www.anipharmaceuticals.com/investors_presentations.php
They trade at 15x forecast EBITDA and 25x historical. Price up 10x since July 13 with a similar model to IDT's new strategy.
Of further interest in the $169m war chest for development, partnerships and accretive acquisitions.
I like IDT exposure to softer AUD, ageing US population with high barriers to entry.
The market wont take long to work this one out, and I think this rerating is in its infancy.
IDT Price at posting:
22.5¢ Sentiment: Buy Disclosure: Held
